{"pmid": "12086367", "sentences": {"sent_1": {"Section": "", "text": "METHODS : After a 1 - week , single - blind , placebo run - in period , 907 male and female patients aged 15 to 82 years were randomized to 1 of 4 treatments : montelukast 10 mg ( n = 155 ) , loratadine 10 mg ( n = 301 ) , combination montelukast 10 mg and loratadine 10 mg ( n = 302 ) , or placebo ( n = 149 ) , administered once daily at bedtime for 2 weeks .", "entities": {"attribute_1": {"text": "1 - week", "class": "measure", "negation": 0, "UMLS": "C1561540:week,", "index": 1, "start": 4}, "entity_1": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "C0032042:placebo,", "index": 2, "start": 12}, "entity_2": {"text": "female", "class": "Participant", "negation": 0, "UMLS": "", "index": 3, "start": 21}, "entity_3": {"text": "aged 15 to 82 years", "class": "Participant", "negation": 0, "UMLS": "", "index": 4, "start": 23}, "attribute_2": {"text": "15 to 82 years", "class": "measure", "negation": 0, "UMLS": "", "index": 5, "start": 24}, "entity_4": {"text": "montelukast 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0298130:montelukast,", "index": 6, "start": 36}, "attribute_3": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 7, "start": 37}, "entity_5": {"text": "loratadine 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0987270:loratadine 10 mg,", "index": 8, "start": 45}, "attribute_4": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 9, "start": 46}, "entity_6": {"text": "combination montelukast 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0298130:montelukast,C3539181:combinations,", "index": 10, "start": 54}, "attribute_5": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 11, "start": 56}, "entity_7": {"text": "loratadine 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0987270:loratadine 10 mg,", "index": 12, "start": 59}, "attribute_6": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 13, "start": 60}, "entity_8": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "C0032042:placebo,", "index": 14, "start": 69}}, "relations": {}}, "sent_2": {"Section": "", "text": "The primary endpoint was the daytime nasal symptoms score ( mean of congestion , rhinorrhea , pruritus , and sneezing ) .", "entities": {"entity_9": {"text": "daytime nasal symptoms score", "class": "Outcome", "negation": 0, "UMLS": "C0231918:nasal symptoms,", "index": 1, "start": 5}, "entity_10": {"text": "congestion", "class": "Outcome", "negation": 0, "UMLS": "C0700148:congestion,", "index": 2, "start": 12}, "entity_11": {"text": "rhinorrhea", "class": "Outcome", "negation": 0, "UMLS": "C1260880:rhinorrhea,", "index": 3, "start": 14}, "entity_12": {"text": "pruritus", "class": "Outcome", "negation": 0, "UMLS": "C0033774:pruritus,", "index": 4, "start": 16}, "entity_13": {"text": "sneezing )", "class": "Outcome", "negation": 0, "UMLS": "C0037383:sneezing,", "index": 5, "start": 19}}, "relations": {}}}}